Abstract
Objective
To investigate the pathological diagnosis, surgical treatment and prognosis of gastrointestinal stromal tumors (GIST).
Methods
The clinicopathological data of 96 post-operative cases with GIST were analyzed retrospectively, and expression of immunohistochemical staining of CD117, CD34, SMA and S -100 was determined.
Results
Immunohistochemical positive staining showed: CD117, 79.1% (76/96); CD34, 58.3% (56/96); SMA, 35.4% (34/96); S-100, 9.3% (9/96). Twenty-three benign cases and 73 malignant cases were reported. The omentums were resected in 39 malignant cases. For the other 34 malignant cases the omentums were left intact. The recurrent and metastatic rates were 5.1% and 26.5%(P<0.05). The incisai section between the normal bowel and the tumor was >5cm in 46 cases, for the other 27 cases, the section was < 5cm. The recurrent and metastatic rates were 6.5% and 29.6%(P<0.05), respectively. The 5-year survival rates of benign and malignant GIST were 91.5% and 57.3%(P<0.05).
Conclusion
GIST were the most freuquent mesenchymal tumor seen in the gastrointestinal tract. The application of immunohistochemical markers CD117and CD34 are mutually beneficial for a final correct pathological diagnosis. The adaptation of a primary rational treatment, including the complete tumor resection and preventive omentectomy could reduce the recurrence of GIST.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Emory Ts, Sobin LH, Lukes L, et al. Prognosis of
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c -kit in human gastrointestinal stromal tumors. Science. 1997;279: 577–580.
Dematteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231;51–58.
Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459–465.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c -kit in human gastrointestinal stromal tumor. Science. 1998;279:577–580.
Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999, 59:4297–4300.
Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215:68–77.
Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269.
Dematteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.
Demetri GD, Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Lou, Y., Zhang, X., Chen, H. et al. Clinical analysis of diagnosis and treatment of gastrointestinal stromal tumors (report of 96 cases). Chin. J. Clin. Oncol. 1, 121–125 (2004). https://doi.org/10.1007/BF02759460
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02759460